Prima BioMed (IMMP) Stock Price, News & Analysis

Company Overview

Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its principal programs included LAG-3–targeted therapies, including IMP321, later known as eftilagimod alpha or efti, an investigational soluble LAG-3 protein intended to stimulate immune responses when used alone or in combination with other cancer treatments. Prima BioMed also developed IMP701, an antibody program targeting the LAG-3 pathway that was subsequently partnered and advanced under different ownership.

In 2014, Prima BioMed changed its name to Immutep Limited and continued its operations under the Immutep name. The company has conducted research and clinical development activities internationally, including in Australia, Europe and the United States. Marc Voigt has served as Immutep’s chief executive officer during the company’s development as a clinical-stage biotechnology business.

Key Stats

• Today's Range: $4.13 to $4.31
• 50-Day Range: $4.27 to $8.07
• 52-Week Range: $4.13 to $70.60
• Volume: 4,987 shs
• Average Volume: 251,169 shs
• Market Capitalization: $30.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $110.00
• Consensus Rating: Hold

Prima BioMed Stock Analysis - MarketRank™

Prima BioMed scored higher than 54% of companies evaluated by MarketBeat, and ranked 434th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Prima BioMed has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Prima BioMed has a consensus price target of $110.00, representing about 2,503.6% upside from its current price of $4.23.

Amount of Analyst Coverage

Prima BioMed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Prima BioMed has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.68% of the float of Prima BioMed has been sold short.

Short Interest Ratio / Days to Cover

Prima BioMed has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Prima BioMed has recently decreased by 8.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prima BioMed does not currently pay a dividend.

Dividend Growth

Prima BioMed does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for IMMP on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Prima BioMed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prima BioMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.07% of the stock of Prima BioMed is held by insiders.

Percentage Held by Institutions

2.32% of the stock of Prima BioMed is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/07/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMMP
• CIK: 1506184
• Web: www.immutep.com
• Phone: (128) 315-7003
• Fax: 61-2-8569-1880
• Employees: 53
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Prima BioMed: $110.00
• High Price Target: $200.00
• Low Price Target: $20.00
• Potential Upside/Downside: +2,525.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.69
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $16.40 million
• Price / Sales: 1.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.67 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 7,370,000
• Free Float: 7,143,000
• Market Cap: $30.88 million
• Optionable: Optionable
• Beta: 2.27